Search research articles
Contact Us
Filters
Showing results (501-510 of 584) with videos related to
Page
of 59
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1996
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer
G J Creemers, C J Gerrits, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects
M J de Jonge, W J Loos, H Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2009
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
J J E M Kitzen, M J A de Jonge, C H J Lamers, et al.
Allergy
|
December 30, 2016
Opisthorchis felineus negatively associates with skin test reactivity in Russia-EuroPrevall-International Cooperation study
O S Fedorova, J J Janse, L M Ogorodova, et al.
Microbial Genomics
|
April 12, 2021
Genome-wide analysis in <i>Escherichia coli</i> unravels a high level of genetic homoplasy associated with cefotaxime resistance
Jordy P M Coolen, Evert P M den Drijver, Jaco J Verweij, et al.
Journal of Medical Virology
|
October 26, 2023
First description and phylogenetic analysis of coxsackie virus A non-polio enteroviruses and parechoviruses A in South Sudanese children
Karen Couderé, Kimberley Benschop, Astrid van Steen, et al.
British Journal of Cancer
|
April 17, 2003
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients
F E de Jongh, R N van Veen, S J Veltman, et al.
Anti-Cancer Drugs
|
November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
A Sparreboom, A S Planting, R C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
C J Gerrits, J H Schellens, H Burris, et al.
Nature Cell Biology
|
June 17, 2024
CD63 sorts cholesterol into endosomes for storage and distribution via exosomes
Roberta Palmulli, Mickaël Couty, Melissa C Piontek, et al.
Page
of 59
Search research articles
Search
Showing results (501-510 of 584) with videos related to
Sort By:
Page
of 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1996
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer
G J Creemers, C J Gerrits, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects
M J de Jonge, W J Loos, H Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2009
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
J J E M Kitzen, M J A de Jonge, C H J Lamers, et al.
Allergy
|
December 30, 2016
Opisthorchis felineus negatively associates with skin test reactivity in Russia-EuroPrevall-International Cooperation study
O S Fedorova, J J Janse, L M Ogorodova, et al.
Microbial Genomics
|
April 12, 2021
Genome-wide analysis in <i>Escherichia coli</i> unravels a high level of genetic homoplasy associated with cefotaxime resistance
Jordy P M Coolen, Evert P M den Drijver, Jaco J Verweij, et al.
Journal of Medical Virology
|
October 26, 2023
First description and phylogenetic analysis of coxsackie virus A non-polio enteroviruses and parechoviruses A in South Sudanese children
Karen Couderé, Kimberley Benschop, Astrid van Steen, et al.
British Journal of Cancer
|
April 17, 2003
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients
F E de Jongh, R N van Veen, S J Veltman, et al.
Anti-Cancer Drugs
|
November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
A Sparreboom, A S Planting, R C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
C J Gerrits, J H Schellens, H Burris, et al.
Nature Cell Biology
|
June 17, 2024
CD63 sorts cholesterol into endosomes for storage and distribution via exosomes
Roberta Palmulli, Mickaël Couty, Melissa C Piontek, et al.
Page
of 59